Eyelid edema as first manifestation of anti‐MDA5 positive dermatomyositis with rapidly progressive interstitial lung disease: A case report
暂无分享,去创建一个
[1] K. Hirata,et al. Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report , 2018, BMC Research Notes.
[2] R. Vleugels,et al. Anti‐melanoma differentiation–associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features , 2017, Journal of the American Academy of Dermatology.
[3] M. Fujimoto,et al. Antimelanoma differentiation‐associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis , 2017, The British journal of dermatology.
[4] R. Hohlfeld,et al. Guidelines on dermatomyositis – excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology , 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[5] F. Liotta,et al. MDA5-positive dermatomyositis: an uncommon entity in Europe with variable clinical presentations , 2015, Clinical and Molecular Allergy.
[6] L. Chung,et al. Cutaneous Ulceration in Dermatomyositis: Association With Anti–Melanoma Differentiation–Associated Gene 5 Antibodies and Interstitial Lung Disease , 2015, Arthritis care & research.
[7] N. McHugh,et al. Myositis Specific and Associated Autoantibodies in the Diagnosis and Management of Juvenile and Adult Idiopathic Inflammatory Myopathies , 2014, Current Rheumatology Reports.
[8] E. Chan,et al. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. , 2014, Clinical and experimental rheumatology.
[9] T. Fujita,et al. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease , 2013, Modern rheumatology.
[10] M. Akiyama,et al. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. , 2012, Rheumatology.
[11] L. Chung,et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. , 2011, Journal of the American Academy of Dermatology.
[12] T. Nishikawa,et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. , 2005, Arthritis and rheumatism.